160 related articles for article (PubMed ID: 1432922)
1. How the FDA and the ADA affect development of prescription drugs for oral care.
Cooley WE
J Public Health Dent; 1992; 52(6):350-2. PubMed ID: 1432922
[TBL] [Abstract][Full Text] [Related]
2. A researcher's view.
Horowitz HS
J Public Health Dent; 1992; 52(6):383-6. PubMed ID: 1432932
[TBL] [Abstract][Full Text] [Related]
3. Effect of regulatory and professional guidelines on the development and marketing of a dental device: case history.
Ross CB
J Public Health Dent; 1992; 52(6):375-7. PubMed ID: 1432929
[TBL] [Abstract][Full Text] [Related]
4. Voluntary programs: ADA Seal program and international implications.
Meyer DM
Ann Periodontol; 1997 Mar; 2(1):31-41. PubMed ID: 9151541
[TBL] [Abstract][Full Text] [Related]
5. The how and why of the ADA's evaluation program for dental therapeutic products.
Whall CW
J Public Health Dent; 1992; 52(6):338-42. PubMed ID: 1432919
[TBL] [Abstract][Full Text] [Related]
6. Legal and regulatory developments of the 1990s in oral care products: learning from what has come before.
O'Reilly JT
J Public Health Dent; 1992; 52(6):396-400. PubMed ID: 1432936
[TBL] [Abstract][Full Text] [Related]
7. Professionally applied and prescribed fluoride products.
Grodberg MG
J Public Health Dent; 1992; 52(6):346-9. PubMed ID: 1432921
[TBL] [Abstract][Full Text] [Related]
8. FDA regulation of OTC oral health care drug products.
Rippere JL
J Public Health Dent; 1992; 52(6):329-32. PubMed ID: 1432917
[TBL] [Abstract][Full Text] [Related]
9. Consumer understanding of the scope of FDA's prescription drug regulatory oversight: A nationally representative survey.
Sullivan HW; Aikin KJ; David KT; Berktold J; Stein KL; Hoverman VJ
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):134-140. PubMed ID: 31833141
[TBL] [Abstract][Full Text] [Related]
10. Legal implications of using drugs and devices in the dental office.
Wakeen LM
J Public Health Dent; 1992; 52(6):403-8. PubMed ID: 1432938
[TBL] [Abstract][Full Text] [Related]
11. FDA approval of comparative claims for prescription drugs--the Moxam case.
Marcus D
Drug Inf J; 1983; 17(3):171-5. PubMed ID: 10265094
[TBL] [Abstract][Full Text] [Related]
12. The Conundrum of Online Prescription Drug Promotion Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".
Wanasika I
Int J Health Policy Manag; 2016 Mar; 5(6):391-2. PubMed ID: 27285519
[TBL] [Abstract][Full Text] [Related]
13. Introduction to the new prescription drug labeling by the Food and Drug Administration.
Lal R; Kremzner M
Am J Health Syst Pharm; 2007 Dec; 64(23):2488-94. PubMed ID: 18029957
[TBL] [Abstract][Full Text] [Related]
14. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
Ostroff C; Lee CE; McMeekin J
Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
[TBL] [Abstract][Full Text] [Related]
15. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
16. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
17. The ADA guidelines on oral malodor products.
Wozniak WT
Oral Dis; 2005; 11 Suppl 1():7-9. PubMed ID: 18488297
[TBL] [Abstract][Full Text] [Related]
18. Interactions as seen by an industry representative among the FDA, the ADA, and industry in preparing a restorative material for market.
Dougherty EW
J Public Health Dent; 1992; 52(6):371-2. PubMed ID: 1432927
[TBL] [Abstract][Full Text] [Related]
19. The "treatment IND (investigational new drugs)": public policy considerations.
Roberts C; Palumbo FB
J Pharm Mark Manage; 1988; 3(1):41-59. PubMed ID: 10290888
[TBL] [Abstract][Full Text] [Related]
20. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
